60978 Federal Register / Vol. 65, No. 199 / Friday, October 13, 2000 / Notices

the basic classes of controlled

substances listed below:

Drug Schedule

Oxycodone (9143) ........................ II

Hydrocodone (9193) ..................... II

Oxymorphone (9652) ................... II

The firm plans to manufacture the

listed controlled substances to make

finished products.

DEA has considered the factors in

Title 21, United States Code, Section

823(a) and determined that the

registration of Dupont Pharmaceuticals

to manufacture the listed controlled

substances is consistent with the public

interest at this time. DEA has

investigated Dupont Pharmaceuticals on

a regular basis to ensure that the

company’s continued registration is

consistent with the public interest.

These investigations have included

inspection and testing of the company’s

physical security systems, verification

of the company’s compliance with state

and local laws, and a review of the

company’s background and history.

Therefore, pursuant to 21 U.S.C. 823

and 28 CFR 0.100 and 0.104, the Deputy

Assistant Administrator, Office of

Diversion Control, hereby orders that

the application submitted by the above

firm for registration as a bulk

manufacturer of the basic classes of

controlled substances listed above is

granted.

Dated: August 18, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–26367 Filed 10–12–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on August 3,

2000, Guilford Pharmaceuticals, Inc.,

6611 Tributary Street, Baltimore,

Maryland 21224, made application by

renewal to the Drug Enforcement

Administration (DEA) for registration as

a bulk manufacturer of cocaine (9041) a

basic class of controlled substance listed

in Schedule II.

The firm plans to manufacture

methyl-3-beta-(4-

trimethylstannylphenyl)-tropane-2-

carboxylate as a final intermediate for

the production of dopascan injection.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substance

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, DC 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than

December 12, 2000.

Dated: September 26, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–26373 Filed 10–12–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on August 4,

2000, Irix Pharmaceuticals, Inc., 101

Technology Place, Florence, South

Carolina 29501, made application by

renewal to the Drug Enforcement

Administration (DEA) for registration as

a bulk manufacturer of methylphenidate

(1724), a basic class of controlled

substance listed in Schedule II.

The firm plans to manufacture

methylphenidate for demonstration

purposes and for dosage form

development and stability studies.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substance

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, DC 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than

December 12, 2000.

Dated: September 28, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–26371 Filed 10–12–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated June 21, 2000, and

published in the Federal Register on

July 3, 2000 (65 FR 41093), ISP

Freetown Chemicals, Inc., 2328 South

Main Street, Assonet, Massachusetts

02702, made application by letter to the

Drug Enforcement Administration

(DEA) to be registered as a bulk

manufacturer of the basic classes of

controlled substances listed below:

Drug Schedule

Amphetamine (1100) .................... II

Phenylacetone (8501) .................. II

The firm plans to bulk manufacture

amphetamine for a customer and to bulk

manufacture the phenylacetone for the

manufacture of the amphetamine.

No comments or objections have been

received. DEA has considered the

factors in Title 21, United States Code,

Section 823(a) and determined that the

registration of ISP Freetown Chemicals,

Inc. to manufacture the listed controlled

substances is consistent with the public

interest at this time. DEA has

investigated ISP Freetown Chemicals,

Inc. to ensure that the company’s

registration is consistent with the public

interest.

This investigation included

inspection and testing of the company’s

physical security systems, verification

of the company’s compliance with state

and local laws, and a review of the

company’s background and history.

Therefore, pursuant to 21 U.S.C. 823

and 28 CFR 0.100 and 0.104, the Deputy

Assistant Administrator, Office of

Diversion Control, hereby orders that

the application submitted by the above

firm for registration as a bulk

manufacturer of the a basic classes of

controlled substances listed above is

granted.

Dated: October 4, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–26369 Filed 10–12–00; 8:45 am]

BILLING CODE 4410–09–M